Supraventricular Tachycardia Induced by Cisplatin in a Patient with Breast Cancer: A Case Report

Sidhi Laksono, Hillary Kusharsamita

Abstract


Introduction: Cisplatin is one of the most extensively used chemotherapeutic agents for treating many malignancies. Cisplatin chemotherapy, on the other hand, is linked to cardiotoxicity, which may vary from silent arrhythmias to heart failure to sudden cardiac death. In this article, we describe a case of supraventricular tachycardia induced by cisplatin in a breast cancer patient.

 

Case Presentation: Our patient had no history of heart disease and had SVT during cisplatin administration. This condition resolved when the infusion was stopped and amiodarone was administered intravenously. The electrolyte levels were within the usual range. No abnormalities were detected on her echocardiography imaging. Primary cardiotoxicity from cisplatin was subsequently determined to be this patient's root cause of SVT. The patient also had an excellent response to the subsequent cycles of treatment.

 

Conclusions: It is important to note that cisplatin therapy is associated with cardiac toxicity. Arrhythmias such as SVT have been associated with chemotherapy drugs. Hence the ECG has to be closely monitored during cisplatin administration. In addition, An ECG and echocardiogram should be done regularly to rule out the possibility of a secondary form of chemotherapy-induced arrhythmia.

 


Keywords


breast cancer, cardiotoxicity, cisplatin, supraventricular

Full Text: View | Download

DOI: 10.33371/ijoc.v18i2.1066

Article Metrics

Abstract View: 83,
PDF Download: 33
             

References


Santos JH, Beyer AM, Terwoord JD, Bikomeye JC. Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol [Internet]. 2022 Oct 1 [cited 2023 Jun 18];323(4):H702–20. Available from: https://pubmed.ncbi.nlm.nih.gov/35930448/

Hu Y, Sun B, Zhao B, Mei D, Gu Q, Tian Z. Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature. Medicine (United States) [Internet]. 2018 Dec 1 [cited 2023 Apr 29];97(52). Available from: https://journals.lww.com/md-journal/Fulltext/2018/12280/Cisplatin_induced_cardiotoxicity_with_midrange.46.aspx

Yu X, Yang Y, Chen T, Wang Y, Guo T, Liu Y, et al. Cell death regulation in myocardial toxicity induced by antineoplastic drugs. Front Cell Dev Biol [Internet]. 2023 Feb 7 [cited 2023 Jun 18];11. Available from: https://pubmed.ncbi.nlm.nih.gov/36824370/

Wang H, Guo S, Kim SJ, Shao F, Kei Ho JW, Wong KU, et al. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics [Internet]. 2021 Jan 1 [cited 2023 Apr 29];11(5):2442. Available from: /pmc/articles/PMC7797698/

Yang X, Li X, Yuan M, Tian C, Yang Y, Wang X, et al. Anticancer therapy-induced atrial fibrillation: Electrophysiology and related mechanisms. Vol. 9, Frontiers in Pharmacology. Frontiers Media S.A.; 2018.

Bjerring AW, Fosså SD, Haugnes HS, Nome R, Stokke TM, Haugaa KH, et al. The cardiac impact of cisplatin-based chemotherapy in survivors of testicular cancer: a 30-year follow-up. Eur Heart J Cardiovasc Imaging [Internet]. 2021 Mar 22 [cited 2023 Jun 18];22(4):443–50. Available from: https://dx.doi.org/10.1093/ehjci/jeaa289

Quryshi N, Norwood Toro LE, Ait-Aissa K, Kong A, Beyer AM. Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. Int J Mol Sci [Internet]. 2018 Mar 10 [cited 2023 Jun 18];19(3). Available from: https://pubmed.ncbi.nlm.nih.gov/29534446/

Lee DH, Chandrashekhar S, Fradley MG. Electrophysiologic Complications in Cancer Patients. Methodist Debakey Cardiovasc J [Internet]. 2019 Oct 1 [cited 2023 Jun 18];15(4):282. Available from: /pmc/articles/PMC6977558/


Refbacks

  • There are currently no refbacks.


Copyright (c) 2024 Sidhi Laksono, Hillary Kusharsamita

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.